First graph, first sentence of release should read: …
The corrected release reads:
preliminary results from the first of two phase III clinical trials of Feraheme
for the treatment of iron deficiency anemia regardless of the underlying
cause after the U.S. financial markets close on
results of this study.
To access the conference call via telephone, please dial (877) 412-6083
telephone replay will be available from approximately
conference call, dial (855) 859-2056. The pass code for the live call
and the replay is 59989211.
The call will be webcast and accessible through the Investors section of
the Company’s website at www.amagpharma.com.
The webcast replay will be available from approximately
development and commercialization of a therapeutic iron compound to
treat iron deficiency anemia. AMAG manufactures and sells Feraheme®
(ferumoxytol) Injection for intravenous use. For additional company or
product information, please visit www.amagpharma.com
Feraheme is a registered trademark of
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303